latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
Published 5 years ago • 487 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
1:47
quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal juncti...
-
6:32
latest results from keynote-181: pembrolizumab versus chemotherapy as a second-line therapy for ...
-
3:14
keynote-062 study: pembrolizumab as treatment for advanced gastroesophageal junction and gastric...
-
3:32
keynote-028 and keynote-158: pembrolizumab as treatment for advanced sclc after two or more line...
-
8:13
has the keynote-189 trial defined a clear standard of care? (bmic-022)
-
58:11
immunotherapy for pancreatic cancer
-
1:59
key objectives in kidney cancer: treatment sequencing & refining clinical endpoints
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
5:05
pembrolizumab vs. standard treatment in patients with recurrent or metastatic head and neck cancer
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
2:38
the immunotherapy promise
-
2:30
association between ttmb and clinical outcomes with pembrolizumab alone in pd-l1-positive advanc...
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
3:07
the keynote-001 trial: a breakthrough for pembrolizumab
-
5:16
keynote-001: five year data from the phase ib trial studying pembrolizumab as treatment for ansclc
-
2:12
real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic uc
-
6:38
lenvatinib plus pembrolizumab for advanced melanoma that progressed on a pd-1 or pd-l1 inhibitor...
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
3:19
frontline pd-l1 monotherapy: keynote-042 and impower110
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma